타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral vectors encoding murine or human IL6/1 were designed using Vector Builder and e |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교